UBS O’Connor expands with healthcare-focused investment team
New York, February 22, 2022 – UBS O’Connor, the multi-strategy hedge fund manager within UBS Asset Management, announced today that it has hired Jason Bonadio MD, Robert Sweeney MD, and Adam Sandler MD to manage a relative value equity strategy focusing on the healthcare therapeutics industry.
Our new investment team at O’Connor brings a combination of biomedical expertise and investment experience that enables us to identify healthcare companies trading well below their intrinsic value. This segment of the market, which has always been prone to high dispersion of returns and high barriers to investment participation, due to the scientific and data complexity of the industry, creates an investment opportunity set ideal for alpha generation and uncorrelated returns.
Kevin Russell, Chief Investment Officer of O’Connor.
Dr. Jason Bonadio joins as a Healthcare Portfolio Manager. Prior to this role, he co-founded Alera Partners, a long/short equity healthcare fund investing in the biotechnology, medical technology, pharmaceutical and life science tools sectors. Dr. Bonadio was also a founding partner and a co-portfolio manager of the FrontPoint Healthcare Funds.
Dr. Robert Sweeney joins as a Healthcare Research Analyst. Dr. Sweeney is a board-eligible surgeon that joined Alera Partners in 2021. Previously, he worked as a sell-side equity research analyst at H.C. Wainwright, with coverage across therapeutic areas and medical devices. He is currently a Ph.D. candidate in Immunology at the Icahn School of Medicine at Mount Sinai in NYC.
Dr. Adam Sandler joins as a Healthcare Research Analyst. Dr. Sandler is currently the chief resident in the Department of Occupational Medicine at Mount Sinai. He joined Alera Partners in 2021 and was previously a healthcare analyst at Guidepoint Global. After graduating, cum laude from Harvard University in 2004, he received awards for his work from the New York Academy of Medicine, Crohn’s and Colitis Foundation of America, and Adenosine Therapeutics at Mount Sinai School of Medicine.
O’Connor has USD 11.2 billion in assets under management as of February 1, 2022. UBS Asset Management is a large scale asset manager with over USD 1.2 trillion in invested assets across its traditional asset management, hedge fund, real estate, infrastructure and private equity businesses.
UBS Asset Management
UBS Asset Management
Asset Management is a large-scale asset manager with a presence in 23 markets. It offers investment capabilities and investment styles across all major traditional and alternative asset classes to institutions, wholesale intermediaries and wealth management clients around the world. It is a leading fund house in Europe, the largest mutual fund manager in Switzerland, the second largest fund of hedge funds manager and one of the largest real assets investment managers in the world.
About UBS O’Connor
About UBS O’Connor
O'Connor is a multi-strategy hedge fund manager within UBS Asset Management, with complete independence in regard to investment decision-making. O’Connor has over 40 years of institutional experience in trading and market making and 20 years’ experience as a hedge fund manager with a strong focus on relative value investing and risk management. O'Connor's capabilities cover a wide range of investment programs and manage over USD 11.2 billion in assets (as of February 1, 2022) on behalf of institutional and high net worth clients. The firm has a global operating platform with offices located in New York, Chicago, Stamford, London, Hong Kong, Shanghai and Singapore.
Make an inquiry
Fill in an inquiry form and leave your details – we’ll be back in touch.
Introducing our leadership team
Meet the members of the team responsible for UBS Asset Management’s strategic direction.